REFERENCES
- Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996;22(5–6):395–407.
- Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15(5):523–536.
- Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000;6(5A):548–554.
- Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16(1):31–42.
- Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89(8):3055–3060.
- Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. SeminOncol 1993;20(Suppl 4):18–25; quiz 26.
- Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17(2):225–230.
- McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? ClinPharmacokinet 2000;39(2):155–165. Review.
- Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;39(7):397–400.
- Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008;14(20): 1936–1949.
- Harvey RD, Shea T, Walko C, Krasnow C, Patel L, Serody J, Gabriel D, Comeau T, Lindley C. Intravenous busulfan test dose clearance comparison with first and thirteenth dose systemic exposure in allogenic bone marrow transplantation patients. Journal of Clinical Oncology, 2005 (ASCO Annual Meeting Proceedings 2005); 23(16S, June 1 Supplement):6658.
- Walko CM, Lindley CM, Collins J, Krasnov C, Harvey RD, Gabriel DA, Serody J, Comeau T, Shea TC. 90 hour continuous intravenous busulfan infusion: PK and test dose predictability in allogenic bone marrow transplantation patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 2005; 23, (16S, Part I of II, June 1 Supplement):6652.
- Walko CM, Shea TC, Rao K, Gabriel D, Serody J, Comeau T, Gilman A, Krasnov C, Lindley CM. Phase I study utilizing an intravenous busulfan test dose to prospectively target and determine the maximum tolerated systemic exposure (MTSE) of a continuous intravenous infusion. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24(18S, June 20 Supplement):16502.
- Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, Shord S, Quigley JG, Chen YH, Mahmud N, Rondelli D. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablativeFluBu conditioning regimen. Bone Marrow Transplant 2010;45(2):249–253.
- Reis EO, Vianna-Jorge R, Suarez-Kurtz G, Silva Lima EL, Almeida Azevedo D. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom 2005;19:1666–1674.